WO2004096982A2 - Antibacterial agents - Google Patents
Antibacterial agents Download PDFInfo
- Publication number
- WO2004096982A2 WO2004096982A2 PCT/US2003/035201 US0335201W WO2004096982A2 WO 2004096982 A2 WO2004096982 A2 WO 2004096982A2 US 0335201 W US0335201 W US 0335201W WO 2004096982 A2 WO2004096982 A2 WO 2004096982A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- substituted
- alkenyl
- hydroxy
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Definitions
- This invention relates to novel compounds, compositions containing them and their use as antibacterials.
- PCT/GB01/05653, PCT/GB01/05661 and WO02040474 disclose quinoline and naphthyridine derivatives having antibacterial activity.
- This invention comprises compounds of the formula (I), as described hereinafter, which are useful in the treatment of bacterial infections.
- This invention is also a pharmaceutical composition comprising a compound according to formula (I) and a pharmaceutically acceptable carrier.
- This invention is also a method of treating bacterial infections in mammals, particularly in humans.
- , ⁇ 2, Z3, Z4 and Z5 is N, one is CR ⁇ 3 and the remainder are CH, or one or two of Z-
- R 1 and R 13 are independently hydrogen; hydroxy; (C ⁇ _ ⁇ )alkoxy unsubstituted or substituted by (C ⁇ _g)alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C- ⁇ ⁇ )alkyl, acyl or (C ⁇ _6)alkylsulphonyl groups, CONH2, hydroxy, (C- ⁇ gJalkylthio, heterocyclyithio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C-
- R 1 is not hydrogen
- A is a substituted or unsubstituted 5 membered aromatic heterocyclic ring of formula (C):
- and W2 are each independently selected from N, O, S, and CR 8 ;
- W3 is N or C;
- W 4 is N, O, S, or CR 8 ;
- each R 8 is independently selected from hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C-i_6)alkylamino; and substituted and unsubstituted (C-
- R 2 is hydrogen, or (C- j _g)alkyl or (C2-6)a'kenyl optionally substituted with 1 to 3 groups selected from: amino optionally substituted by one or two (C-
- R 3 is a group -U-R 4 where
- R 4 is a substituted or unsubstituted bicyclic carbocyclic or heterocyclic ring system (A):
- ring (a) is aromatic and ring (b) is aromatic or non-aromatic;
- X 1 is C;
- X 2 is N or CR 5 ;
- X 3 and X 5 are C;
- Y 1 is a 1 to 2 atom linker group, each atom of which is independently selected from N and CR 5 ;
- Y 2 is a 2 to 6 atom linker group, each atom of Y 2 being independently selected from N, NR 7 , O, S(O)x, CO, CR 5 and CR 5 R 6 ;
- each of R 5 and R 6 is independently selected from: hydrogen; (C- j _4)alkylthio; halo; carboxy(C- j _4)alkyl; halo(C-
- each R 7 is independently hydrogen; trifluoromethyl; (C ⁇ _4)alkyl unsubstituted or substituted by hydroxy, (C-
- Prodrugs are considered to be any covalently bonded carriers which release the active parent drug according to formula (I) in vivo.
- the invention also provides a pharmaceutical composition, in particular for use in the treatment of bacterial infections in mammals, particularly humans, comprising a compound of formula (I), or a pharmaceutically acceptable derivative thereof, and a pharmaceutically acceptable carrier.
- the invention further provides a method of treatment of bacterial infections in mammals, particularly in humans, which method comprises the administration to a mammal in need of such treatment an effective amount of a compound of formula (I), or a pharmaceutically acceptable derivative thereof.
- Z5 is CH or N
- Z3 is CH or CF and Z- ⁇ , ⁇ 2 and Z4 are each CH
- Z- j is N
- Z3 is CH or CF and Z2
- Z4 and Z5 are each CH.
- R 1 or R " l a is substituted alkoxy it is preferably (C2-g)alkoxy substitituted by optionally N-substituted amino, guanidino or amidino, or (C-
- Suitable examples of R 1 and R ⁇ a alkoxy include methoxy, trifluoromethoxy, n-propyloxy, iso-butyloxy, aminoethyloxy, aminopropyloxy, aminobutyloxy, aminopentyloxy, guanidinopropyloxy, piperidin-4- ylmethyloxy, phthalimido pentyloxy or 2-aminocarbonylprop-2-oxy.
- R 1 and R ⁇ a are independently methoxy, amino(C3_5)alkyloxy, guanidino(C3_5)alkyloxy, piperidyl(C3_5)alkyloxy, nitro or halo. More preferably R 1 and R " l a are independently methoxy, amino(C3_5)alkyloxy or guanidino(C3_ 5)alkyloxy. Most preferably R 1 is methoxy and R 1 a is H or when Z3 is CR 1 a it may be C-F.
- R 1 a is preferably hydrogen, cyano, hydroxymethyl or carboxy, most preferably hydrogen.
- ring (C) examples are substituted and unsubstituted pyrrole, isopyrrole, pyrazole, imidazole, triazole, tetrazole, oxazole, isoxazole, furan, thiophene, thiazole, isothiazole, and oxadiazole.
- ring (C) is substituted or unsubstituted pyrrole, thiophene, furan, thiazole, or triazole.
- ring (C) is triazole or thiazole
- R 8 is hydrogen or (C-
- R 2 is preferably hydrogen; (C-
- Y 2 has 3-5 atoms, more preferably 4 atoms, including NR 7 , O or S bonded to X 5 and NHCO bonded via N to X 3 , or O or NH bonded to X 3 .
- Ring (a) is preferably substituted and unsubstituted phenyl and pyridine.
- ring (b) is substituted and unsubstituted pyridine, dioxane, piperidine, morpholin-3-one, thiomorpholin-3-one, oxazolidin-2-one, thiadiazole, and thiazepan-5-one.
- Examples of ring (A) groups include substituted or unsubstituted: 1 ,1 ,3-trioxo-1 ,2,3,4-tetrahydro1 /6-benzo[1 ,4] thiazin-3-one-6-yl, benzo[1 ,3]dioxol-5- yl, 4H-benzo[1 ,4]oxazin-3-one-6-yl, 2,3-dihydro-benzo[1 ,4]dioxin-6-yl, 2-oxo-2,3- dihydro-benzooxazol-6-yl, 3-substituted-3H-benzooxazol-2-one-6-yl, 3-substituted- 3H-benzooxazole-2-thione-6-yl, 3-substituted-3H-benzothiazol-2-one-6-yl, 4H- benzo[1 ,4]oxazin-3-one-6-yl (3-ox
- R 5 and R are preferably independently selected from hydrogen, halo, hydroxy, (C-j_4)alkoxy, trifluoromethoxy, nitro, cyano, aryl(C-
- each R 5 is selected from hydrogen, chloro, fluoro, hydroxy, methoxy, trifluoromethoxy, benzyloxy, nitro, cyano and methylsulphonyl.
- R 6 is selected from hydrogen, fluorine or nitro.
- R 7 is preferably H if in ring (a) or in addition (C-
- R 4 are:
- Preferred compounds of this invention are:
- .g)alkyl when used alone or when forming part of other groups (such as the 'alkoxy' group) includes substituted or unsubstituted, straight or branched chain alkyl groups containing 1 to 6 carbon atoms.
- _g)alkyl include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert-butyl groups.
- (C2-g)alkenyl means a substituted or unsubstituted alkyl group of 2 to 6 carbon atoms, wherein one carbon-carbon single bond is replaced by a carbon-carbon double bond.
- Examples of (C2-g)alkenyl include ethylene, 1 - propene, 2-propene, 1 -butene, 2-butene, isobutene and the several isomeric pentenes and hexenes. Both cis and trans isomers are included.
- (C3_7)cycloalkyl refers to subsituted or unsubstituted carbocyclic system of three to seven carbon atoms, which may contain up to two unsaturated carbon-carbon bonds.
- Examples of (C3_7)cycloalkyl include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, and cycloheptyl.
- .g)alkyl, (C2- g)alkenyl, and (C3_7)cycloalkyl groups includes up to three substituents selected from the group consisting of hydroxy, halogen, nitro, cyano, carboxy, amino, amidino, sulphonamido, unsubstituted (C-
- Halo or halogen includes fluoro, chloro, bromo and iodo.
- Haloalkyl moieties include 1-3 halogen atoms.
- the term "heterocyclic” as used herein includes optionally substituted aromatic and non-aromatic, single and fused, rings suitably containing up to four hetero-atoms in each ring selected from oxygen, nitrogen and sulphur, which rings may be unsubstituted or C-substituted by, for example, up to three groups selected from (C ⁇ _4)alkylthio; halo; carboxy(C-
- Each heterocyclic ring suitably has from 4 to 7, preferably 5 or 6, ring atoms.
- a fused heterocyclic ring system may include carbocyclic rings and need include only one heterocyclic ring.
- suitable optional substituents in such substituted amino groups include H; trifluoromethyl; (C- j _4)alkyl optionally substituted by hydroxy, (C-
- aryl includes optionally substituted phenyl and naphthyl.
- Aryl groups may be optionally substituted with up to five, preferably up to three, groups selected from (C 1 _4)alkylthio; halo; carboxy(C-j_4)alkyl; halo (C-
- Some of the compounds of this invention may be crystallised or recrystallised from solvents such as aqueous and organic solvents. In such cases solvates may be formed.
- This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
- the compounds of formula (I) are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1 %, more suitably at least 5% and preferably from 10 to 59% of a compound of the formula (I) or pharmaceutically acceptable derivative thereof.
- compositions of the above-mentioned compounds of formula (I) include the free base form or their acid addition or quaternary ammonium salts, for example their salts with mineral acids e.g. hydrochloric, hydrobromic, sulphuric nitric or phosphoric acids, or organic acids, e.g. acetic, fumaric, succinic, maleic, citric, benzoic, p-toluenesulphonic, methanesulphonic, naphthalenesulphonic acid or tartaric acids.
- Compounds of formula (I) may also be prepared as the N-oxide.
- Compounds of formula (I) having a free carboxy group may also be prepared as an in vivo hydrolysable ester. The invention extends to all such derivatives.
- Suitable pharmaceutically acceptable in vivo hydrolysable ester-forming groups include those forming esters which break down readily in the human body to leave the parent acid or its salt. Suitable groups of this type include those of part formulae (i), (ii), (iii), (iv) and (v): R a
- R a is hydrogen, (C- ⁇ g) alkyl, (03.7) cycloalkyl, methyl, or phenyl
- R b is (C-
- Suitable in vivo hydrolysable ester groups include, for example, acyloxy(C-
- a further suitable pharmaceutically acceptable in vivo hydrolysable ester- forming group is that of the formula:
- Rk is hydrogen, (C- ⁇ g)alkyl or phenyl.
- Certain of the above-mentioned compounds of formula (I) may exist in the form of optical isomers, e.g. diastereoisomers and mixtures of isomers in all ratios, e.g. racemic mixtures.
- the invention includes all such forms, in particular the pure isomeric forms.
- the invention includes compound in which an A-B group CH(OH)-CH2 is in either isomeric configuration the ff-isomer is preferred.
- the different isomeric forms may be separated or resolved one from the other by conventional methods, or any given isomer may be obtained by conventional synthetic methods or by stereospecific or asymmetric syntheses.
- Certain reagents are abbreviated herein.
- DCC refers to dicyclohexylcarbodiimide
- DMAP refers to dimethylaminopyridine
- DIEA refers to diisopropylethyl amine
- EDC refers to 1-(3-dimethylaminopropyl)-3- ethylcarbodiimide, hydrochloride.
- HOBt refers to 1 -hydroxybenzotriazole
- THF tetrahydrofuran
- DIEA diisopropylethylamine
- DEAD refers to diethyl azodicarboxylate
- PPh3 refers to triphenylphosphine
- DIAD diisopropyl azodicarboxylate
- DME dimethoxyethane
- DMF dimethylformamide
- NBS refers to N-bromosuccinimide
- Pd/C refers to a palladium on carbon catalyst
- PPA refers to polyphosphoric acid
- DPPA diphenylphosphoryl azide
- BOP refers to benzotriazol-1-yloxy-tris(dimethyl- amino)phosphonium hexafluorophosphate
- HF refers to hydrofluoric acid
- TEA refers to triethylamine
- TFA trifluoroacetic acid
- PCC refers to hydroflu
- Reagents and conditions (a) Trimethylsilylacetylene, Cul, PdCl2(PPh3)2, Et3N, CH2CI2; (b) K2CO3, CH3OH; (c) 2-(3-azidopropyl)isoindole-1 ,3-dione, toluene; (d) N2H4 ⁇ 2O, EtOH; (e) 3-oxo-3,4-dihydro-2 --benzo[1 ,4]thiazine-6-sulfonyl chloride, CHCI 3> Et 3 N.
- Triflate (1-1) is reacted under Sonogashira coupling conditions (Sonogashira, K.; Tohda, Y; Hagihara, N. Tetrahedron Lett. 1975, pp. 4467-4470) with an aromatic halide or aromatic triflate to afford I-2. Removal of the trimethylsilyl protecting group is carried out under basic conditions to give the alkyne I-3.
- the use of protecting groups to mask reactive functionality is well-known to those of skill in the art, and other protecting groups are listed in standard reference volumes, such as Greene, "Protective Groups in Organic Synthesis" (published by Wiley- Interscience).
- the terminal alkyne derivative is then reacted with an azide under thermal cyclization conditions to yield the triazole 1-4.
- phthalamide protecting group is accomplished using hydrazine or other suitable reagents as described in Greene, referenced above, to afford the free amine 1-5.
- the amine is then reacted with a suitable electrophile such as an arylsulfonyl chloride to form the sulfonamide 1-6.
- 3-oxo-3,4-dihydro-2 --benzo[1 ,4]thiazine-6-sulfonyl chloride is converted to a sulfonamide by reaction with an amine in aprotic solvents such as DMF, CH2CI2, CH3CN and using an added base, such as triethylamine (Et3N), diisopropylethylamine ((i-Pr)2NEt), or K2CO3 to scavenge for acid formed in situ .
- Et3N triethylamine
- i-Pr2NEt diisopropylethylamine
- K2CO3 K2CO3
- Reagents and conditions (a) butyl vinyl ether, palladium (II) acetate, 1 ,3- bis(diphenylphosphino)propane , Et3N, DMF; (b) N-bromosuccinimide, THF, H2O; (c) 1 ,1-dimethylethyl (3-amino-3-thioxopropyl)carbamate, ethanol, NaHCO3; (d) trifluoroacetic acid ; (e) methanol/dimethylformamide/acetic acid, 3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1 ,4]thiazine-6-carbaldehyde, sodium cyanoborohydride.
- Triflate (11-1) is reacted under Heck coupling conditions to afford II-2, (for a review, see Beletskaya, Irina P.; Cheprakov, Andrei V., Chemical Reviews (Washington, D. C.) (2000), 100(8), 3009-3066). Reaction of vinyl ether 11-2 with N-bromosuccinimide under aqueous conditions gives bromomethyl ketone 11-3 (see for eaxample, Dhar, T.G. et al , Journal of Medicinal Chemistry (2002), 45(11), 2127-2130).
- compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.
- the antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.
- compositions may be formulated for administration by any route, such as oral, topical or parenteral.
- the compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
- topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
- the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
- suitable conventional carriers such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
- Such carriers may be present as from about 1 % up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
- Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
- the tablets may be coated according to methods well known in normal pharmaceutical practice.
- Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavouring or colouring agents.
- suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
- Suppositories will contain conventional suppository bases, e.g. cocoa-butter or other glyceride.
- fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
- the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
- agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- the dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
- Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
- the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- compositions may contain from 0.1% by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
- the dosage as employed for adult human treatment will preferably range from 100 to 3000 mg per day, for instance 1500 mg per day depending on the route and frequency of administration. Such a dosage corresponds to 1.5 to 50 mg/kg per day. Suitably the dosage is from 5 to 20 mg/kg per day.
- the compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or with a ⁇ -lactamase inhibitor may be employed.
- Compounds of formula (I) are active against a wide range of organisms including both Gram-negative and Gram-positive organisms.
- the compounds used in the antimicrobial assays of the present invention have a MIC value of less than 16 ⁇ g/mL.
- PRP-1® is a polymeric (styrene-divinylbenzene) chromatographic support, and is a registered trademark of Hamilton Co., Reno, Nevada.
- Celite® is a filter aid composed of acid-washed diatomaceous silica, and is a registered trademark of Manville Corp., Denver, Colorado.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60331849T DE60331849D1 (en) | 2002-11-05 | 2003-11-04 | ANTIBACTERIAL ACTIVE SUBSTANCES |
EP03816120A EP1560821B8 (en) | 2002-11-05 | 2003-11-04 | Antibacterial agents |
AT03816120T ATE461928T1 (en) | 2002-11-05 | 2003-11-04 | ANTIBACTERIAL ACTIVE INGREDIENTS |
US10/533,502 US7232832B2 (en) | 2002-11-05 | 2003-11-04 | Antibacterial agents |
JP2004571466A JP4704755B2 (en) | 2002-11-05 | 2003-11-04 | Antibacterial agent |
AU2003303956A AU2003303956A1 (en) | 2002-11-05 | 2003-11-04 | Antibacterial agents |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US42385802P | 2002-11-05 | 2002-11-05 | |
US60/423,858 | 2002-11-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004096982A2 true WO2004096982A2 (en) | 2004-11-11 |
WO2004096982A3 WO2004096982A3 (en) | 2005-02-17 |
Family
ID=33415888
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/035201 WO2004096982A2 (en) | 2002-11-05 | 2003-11-04 | Antibacterial agents |
Country Status (8)
Country | Link |
---|---|
US (1) | US7232832B2 (en) |
EP (1) | EP1560821B8 (en) |
JP (1) | JP4704755B2 (en) |
AT (1) | ATE461928T1 (en) |
AU (1) | AU2003303956A1 (en) |
DE (1) | DE60331849D1 (en) |
ES (1) | ES2340484T3 (en) |
WO (1) | WO2004096982A2 (en) |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
US7312212B2 (en) | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
WO2008009700A1 (en) | 2006-07-20 | 2008-01-24 | Glaxo Group Limited | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
US7491714B2 (en) | 2002-12-04 | 2009-02-17 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
US7498326B2 (en) | 2002-06-26 | 2009-03-03 | Glaxo Group Limited | Compounds |
US7511035B2 (en) | 2005-01-25 | 2009-03-31 | Glaxo Group Limited | Antibacterial agents |
EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
US7592334B2 (en) | 2005-01-25 | 2009-09-22 | Glaxo Group Limited | Antibacterial agents |
US7605169B2 (en) | 2005-01-25 | 2009-10-20 | Glaxo Group Limited | Antibacterial agents |
US7622481B2 (en) | 2002-06-26 | 2009-11-24 | Glaxo Group Limited | Antibacterial compounds |
US7648980B2 (en) | 2005-01-25 | 2010-01-19 | Glaxo Group Limited | Antibacterial agents |
US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
US7709496B2 (en) | 2006-04-06 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
US7709472B2 (en) | 2005-01-25 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
WO2010081874A1 (en) | 2009-01-15 | 2010-07-22 | Glaxo Group Limited | Naphthyridin-2 (1 h)-one compounds useful as antibacterials |
WO2016027249A1 (en) | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200427688A (en) * | 2002-12-18 | 2004-12-16 | Glaxo Group Ltd | Antibacterial agents |
EP1773831A1 (en) * | 2004-07-08 | 2007-04-18 | Glaxo Group Limited | Antibacterial agents |
DE602008002912D1 (en) * | 2007-04-20 | 2010-11-18 | Glaxo Group Ltd | TRICYCLIC NITROGENIC COMPOUNDS AS ANTIBACTERIAL ACTIVE SUBSTANCES |
US10526343B2 (en) | 2018-03-26 | 2020-01-07 | University Of Sharjah | Heterocyclic systems and pharmaceutical applications thereof |
KR20220087497A (en) | 2019-10-18 | 2022-06-24 | 더 리전츠 오브 더 유니버시티 오브 캘리포니아 | Compounds and methods for targeting pathogenic blood vessels |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021948A1 (en) * | 1998-10-14 | 2000-04-20 | Smithkline Beecham Plc | Naphthrydine compounds and their azaisosteric analogues as antibacterials |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0869793A4 (en) | 1995-11-13 | 1999-02-03 | Smithkline Beecham Corp | Hemoregulatory compounds |
DE69908555T2 (en) | 1998-01-26 | 2004-05-06 | Smithkline Beecham P.L.C., Brentford | CHINOLINE DERIVATIVES AS AN ANTIBACTERIAL MEDICINAL PRODUCT |
GB9822440D0 (en) * | 1998-10-14 | 1998-12-09 | Smithkline Beecham Plc | Medicaments |
AU2437900A (en) | 1999-01-20 | 2000-08-07 | Smithkline Beecham Plc | Piperidinylquinolines as protein tyrosine kinase inhibitors |
GB9914486D0 (en) | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
GB9917406D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
GB9917408D0 (en) | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
FR2798656B1 (en) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | DERIVATIVES OF QUINOLYL PROPYL PIPERIDINE, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
US6403610B1 (en) | 1999-09-17 | 2002-06-11 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation and the compositions which comprise them |
US6803369B1 (en) * | 2000-07-25 | 2004-10-12 | Smithkline Beecham Corporation | Compounds and methods for the treatment of neoplastic disease |
PL366335A1 (en) * | 2000-07-26 | 2005-01-24 | Smithkline Beecham P.L.C. | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
DE60119939T2 (en) * | 2000-09-21 | 2006-11-30 | Smithkline Beecham P.L.C., Brentford | CHINOLINE DERIVATIVES AS ANTIBACTERIAL AGENTS |
WO2002036667A1 (en) * | 2000-11-06 | 2002-05-10 | Denki Kagaku Kogyo Kabushiki Kaisha | Conductive polypropylene resin foam sheet and receptacle |
US6603005B2 (en) | 2000-11-15 | 2003-08-05 | Aventis Pharma S.A. | Heterocyclylalkylpiperidine derivatives, their preparation and compositions containing them |
FR2816618B1 (en) | 2000-11-15 | 2002-12-27 | Aventis Pharma Sa | HETEROCYCLYLALCOYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
GB0031086D0 (en) * | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
US6602884B2 (en) | 2001-03-13 | 2003-08-05 | Aventis Pharma S.A. | Quinolylpropylpiperidine derivatives, their preparation, and compositions containing them |
FR2822154B1 (en) | 2001-03-13 | 2005-10-21 | Aventis Pharma Sa | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM |
GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
EP1280180A3 (en) * | 2001-07-25 | 2005-02-09 | Lg.Philips Displays Korea Co., Ltd. | Electron gun for cathode ray tube |
US20030203917A1 (en) | 2001-07-25 | 2003-10-30 | Smithkline Beecham Corporation And Smithkline Beecham P.L.C. | Compounds and methods for the treatment of neoplastic disease |
GB0118238D0 (en) * | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
EP1470131A2 (en) | 2002-01-29 | 2004-10-27 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
US7312212B2 (en) * | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
TW200406413A (en) * | 2002-06-26 | 2004-05-01 | Glaxo Group Ltd | Compounds |
GB0217294D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicaments |
FR2844270B1 (en) | 2002-09-11 | 2006-05-19 | Aventis Pharma Sa | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, THEIR PROCESS AND PREPARATION INTERMEDIATES AND THE COMPOSITIONS CONTAINING THEM |
FR2844268B1 (en) | 2002-09-11 | 2004-10-22 | Aventis Pharma Sa | QUINOLYL PROPYL PIPERIDINE DERIVATIVES, PROCESSES AND INTERMEDIATES FOR THEIR PREPARATION, AND COMPOSITIONS CONTAINING THEM |
ATE463494T1 (en) | 2002-10-10 | 2010-04-15 | Morphochem Ag Komb Chemie | NEW COMPOUNDS WITH ANTIBACTERIAL ACTIVITY |
EP1560488B1 (en) | 2002-11-05 | 2010-09-01 | Glaxo Group Limited | Antibacterial agents |
CA2505990C (en) * | 2002-11-15 | 2009-05-19 | Helsinn Healthcare S.A. | Palonosetron for the treatment of chemotherapy-induced emesis |
EP1567520B1 (en) | 2002-12-04 | 2008-10-15 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
TW200427688A (en) | 2002-12-18 | 2004-12-16 | Glaxo Group Ltd | Antibacterial agents |
TW200507841A (en) | 2003-03-27 | 2005-03-01 | Glaxo Group Ltd | Antibacterial agents |
FR2852954B1 (en) | 2003-03-28 | 2006-07-14 | Aventis Pharma Sa | QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US7232833B2 (en) | 2003-03-28 | 2007-06-19 | Novexel | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
DE10316081A1 (en) | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | New compounds with antibacterial activity |
FR2858619B1 (en) | 2003-08-08 | 2006-12-22 | Aventis Pharma Sa | QUINOLINE-4-SUBSTITUTED DERIVATIVES, METHODS AND PREPARATION INTERMEDIATES THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
US7348434B2 (en) | 2003-08-08 | 2008-03-25 | Antony Bigot | 4-substituted quinoline derivatives, method and intermediates for their preparation and pharmaceutical compositions containing them |
MY144477A (en) * | 2004-03-17 | 2011-09-30 | Novartis Ag | Galenic formulations of organic compounds |
-
2003
- 2003-11-04 ES ES03816120T patent/ES2340484T3/en not_active Expired - Lifetime
- 2003-11-04 EP EP03816120A patent/EP1560821B8/en not_active Expired - Lifetime
- 2003-11-04 WO PCT/US2003/035201 patent/WO2004096982A2/en active Application Filing
- 2003-11-04 AU AU2003303956A patent/AU2003303956A1/en not_active Abandoned
- 2003-11-04 AT AT03816120T patent/ATE461928T1/en not_active IP Right Cessation
- 2003-11-04 US US10/533,502 patent/US7232832B2/en not_active Expired - Fee Related
- 2003-11-04 JP JP2004571466A patent/JP4704755B2/en not_active Expired - Fee Related
- 2003-11-04 DE DE60331849T patent/DE60331849D1/en not_active Expired - Lifetime
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000021948A1 (en) * | 1998-10-14 | 2000-04-20 | Smithkline Beecham Plc | Naphthrydine compounds and their azaisosteric analogues as antibacterials |
Non-Patent Citations (1)
Title |
---|
See also references of EP1560821A2 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7312212B2 (en) | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
US7109213B2 (en) | 2002-01-29 | 2006-09-19 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
US7622481B2 (en) | 2002-06-26 | 2009-11-24 | Glaxo Group Limited | Antibacterial compounds |
US7498326B2 (en) | 2002-06-26 | 2009-03-03 | Glaxo Group Limited | Compounds |
US7491714B2 (en) | 2002-12-04 | 2009-02-17 | Glaxo Group Limited | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
US7691850B2 (en) | 2004-06-15 | 2010-04-06 | Glaxo Group Limited | Antibacterial agents |
US7709472B2 (en) | 2005-01-25 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
US7511035B2 (en) | 2005-01-25 | 2009-03-31 | Glaxo Group Limited | Antibacterial agents |
US7592334B2 (en) | 2005-01-25 | 2009-09-22 | Glaxo Group Limited | Antibacterial agents |
US7605169B2 (en) | 2005-01-25 | 2009-10-20 | Glaxo Group Limited | Antibacterial agents |
US7759340B2 (en) | 2005-01-25 | 2010-07-20 | Glaxo Group Limited | Antibacterial agents |
US7648980B2 (en) | 2005-01-25 | 2010-01-19 | Glaxo Group Limited | Antibacterial agents |
WO2007115947A1 (en) | 2006-04-06 | 2007-10-18 | Glaxo Group Limited | Pyrrolo-quinoxalinone derivatives as antibacterials |
US7709496B2 (en) | 2006-04-06 | 2010-05-04 | Glaxo Group Limited | Antibacterial agents |
WO2008009700A1 (en) | 2006-07-20 | 2008-01-24 | Glaxo Group Limited | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
EP2080761A1 (en) | 2008-01-18 | 2009-07-22 | Glaxo Group Limited | Compounds |
WO2010043714A1 (en) | 2008-10-17 | 2010-04-22 | Glaxo Group Limited | Tricyclic nitrogen compounds used as antibacterials |
WO2010081874A1 (en) | 2009-01-15 | 2010-07-22 | Glaxo Group Limited | Naphthyridin-2 (1 h)-one compounds useful as antibacterials |
WO2016027249A1 (en) | 2014-08-22 | 2016-02-25 | Glaxosmithkline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
EP3639824A1 (en) | 2014-08-22 | 2020-04-22 | GlaxoSmithKline Intellectual Property Development Limited | Tricyclic nitrogen containing compounds for treating neisseria gonorrhoea infection |
WO2017029602A2 (en) | 2015-08-16 | 2017-02-23 | Glaxosmithkline Intellectual Property Development Limited | Compounds for use in antibacterial applications |
Also Published As
Publication number | Publication date |
---|---|
DE60331849D1 (en) | 2010-05-06 |
WO2004096982A3 (en) | 2005-02-17 |
EP1560821A4 (en) | 2007-07-25 |
AU2003303956A1 (en) | 2004-11-23 |
EP1560821B1 (en) | 2010-03-24 |
ATE461928T1 (en) | 2010-04-15 |
US7232832B2 (en) | 2007-06-19 |
JP4704755B2 (en) | 2011-06-22 |
AU2003303956A8 (en) | 2004-11-23 |
EP1560821A2 (en) | 2005-08-10 |
US20060166977A1 (en) | 2006-07-27 |
ES2340484T3 (en) | 2010-06-04 |
EP1560821B8 (en) | 2010-05-19 |
JP2006510729A (en) | 2006-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1560488B1 (en) | Antibacterial agents | |
EP1560821B1 (en) | Antibacterial agents | |
EP1605938B1 (en) | Antibacterial derivatives of napthydrin and quinoline | |
EP1392686B1 (en) | Bicyclic nitrogen-containing heterocyclic derivatives for use as antibacterials | |
JP4515260B2 (en) | Aminocyclohexene quinoline and its azaisosteric analogs with antibacterial activity | |
US7605169B2 (en) | Antibacterial agents | |
EP1781669B1 (en) | Antibacterial agents | |
US20070203127A1 (en) | Antibacterial Agents | |
US20080194547A1 (en) | Antibacterial Agents | |
JP2008528588A (en) | Antibacterial agent | |
JP2008528587A (en) | Antibacterial agent | |
US7491714B2 (en) | Quinolines and nitrogenated derivatives thereof and their use as antibacterial agents |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AU BA BB BR BZ CA CN CO CR CU DM DZ EC EG GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SC SG TN TT UA US UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2006166977 Country of ref document: US Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003816120 Country of ref document: EP Ref document number: 10533502 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004571466 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2003816120 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10533502 Country of ref document: US |